Le Lézard
Classified in: Health
Subjects: PARTNERSHIPS, HEALTH

AllStar Health Shareholder Update


MIAMI, Sept. 21, 2021 (GLOBE NEWSWIRE) -- AllStar Health Brands (OTC Pink: ALST) has opted to issue a shareholder update as there are a number of initiatives that are now coming to fruition.

ALST has formed a strategic partnership with Virotek Biosciences Inc., to facilitate the application of the rapid COVID test to the various AllStar commercial, industrial and civic customers. Agreeing to regular testing appears to be one of the alternatives that some employers will accept in place of double dose vaccine. This opens the way for services such as the ALST- Virotek partnership to complete those tests.

The Company has also entered into the testing phase of the new web site https://vividcbd.com/. We have secured a contracted supply of the product, we have the rights to expand into other product lines, and we have the systems in place to start taking orders over the next few days.

"All of our efforts to bring to market different services and different product offerings are about to start paying off," said Pete Wanner, CEO of ALST. "Our sales pipelines are eager to have these services and products become available to them and we anticipate a rapid acceptance of these new products from our existing clients."

About AllStar Health Brands (ALST)

AllStar Health Brands has a number of distribution networks that involve sales of nutraceutical and other health equipment to various countries in the Western Hemisphere. Hospital equipment, health testing, PPE have dominated the Company's activities over the last 18 months, but in that time, the Company also formed contacts for supply and for sale, largely in the US and Canada, but also stretching into other Western Hemisphere countries. The ability to move PPE, testing suppliers and health equipment is now being enhanced with Nutraceutical products, which can be moved along the same distribution networks already established.

This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to a number of risks and uncertainties, many of which are outside AllStar's control. These include but are not limited to the impact of competitors' products, services and pricing; product demand; market acceptance; new product development; reliance on key strategic alliances; the regulatory environment; fluctuations in operating results; and other risks which are detailed from time to time in the Company's filings with the Securities and Exchange Commission and/or OTC Markets. AllStar Health Brands Inc disclaims any obligation to update or alter its forward-looking statements whether as a result of new information, subsequent events or otherwise.

CONTACT:AllStar Health Brands
 Peter Wanner, CEO
 [email protected]
 www.allstarhealthbrands.com


These press releases may also interest you

at 16:20
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The...

at 16:15
eHealth, Inc. , a leading private online health insurance marketplace (the "Company"), today announced that on July 1, 2024, the Compensation Committee of its Board of Directors granted inducement stock unit awards to two new employees covering an...

at 16:10
bluebird bio, Inc. today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James...

at 16:10
The global consumer healthcare market size is estimated to grow by USD 170.2 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period. Awareness about lifestyle diseases is driving...

at 16:05
Voomtm Medical Devices, Inc. ("Voom"), the orthopedic medical device company behind the disruptive, game-changing Revcontm bunion screw technology, is honored to be named first on Podiatry Today's 2024 Top 10 Innovations list. Voom's one-of-a-kind...

at 16:05
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation...



News published on and distributed by: